脂肪異栄養症 - 市場考察、疫学、市場予測（2034年）

主なハイライト

• 脂肪異栄養症は、体脂肪の異常な分布を特徴とするまれな疾患です。脂肪組織が消失したり（脂肪萎縮症）、体の異常な部位に脂肪が蓄積したり（脂肪肥大症）します。
• DelveInsightの2023年の推計によると、希少疾患である脂肪異栄養症の患者数は主要7市場全体で約3,077人で、米国がその35%を占めます。
• 2023年、診断された脂肪異栄養症患者の93%は部分的脂肪異栄養症であり、主に女性が罹患しています。これは、一般的なタイプである家族性部分的脂肪異栄養症（FPL）がLMNAまたはPPARG遺伝子の遺伝子変異と関連しており、女性に多くみられることが主な理由です。
• 2023年、米国の脂肪異栄養症患者の約30%が先天性全般性脂肪異栄養症に分類されました。この疾患は、体脂肪がほぼ完全に失われ、筋肉が隆起し、重度のインスリン抵抗性、早期発症糖尿病、高トリグリセリド血症、非アルコール性脂肪性肝疾患（NAFLD）を引き起こします。
• 米国FDAは、脂肪異栄養症治療薬として、Amryt PharmaのMYALEPT（metreleptin）とThera TechnologiesのEGRIFTA/EGRIFTA SV（tesamorelin）を承認しています。
• 脂肪異栄養症のパイプラインはまだ比較的限られており、数社が候補品をさまざまな段階の臨床試験に進めているのみです。RegeneronのREGN4461は現在フェーズIIにあります。脂肪異栄養症の希少性は、臨床試験の患者募集に課題をもたらし、ひいては新治療法オプションの開発の進捗を遅らせます。
• 米国が脂肪異栄養症市場で最大のシェアを占めているのは、この疾患の高い有病率と、承認された治療薬があることによるものです。Amryt PharmaのMYALEPT（metreleptin）は、レプチンをベースとした治療で大きな収益をあげている主要企業です。

脂肪異栄養症市場の見通し

脂肪異栄養症治療市場は、既存治療法と新治療法の両方に注力しながら発展しています。米国では、MYALEPT（metreleptin）やEGRIFTA/EGRIFTA SV（tesamorelin）などの主な承認治療薬が市場を独占しており、これらの治療薬が収益に大きく寄与しています。

• 米国は脂肪異栄養症市場で最大のシェアを占めており、これはこの疾患の高い有病率と承認された治療法の利用可能性によるものです。Amryt PharmaのMYALEPT（metreleptin）は主要企業であり、レプチンをベースとした治療により約88万米ドルという大きな収益を上げています。
• 欧州4ヶ国と英国の中で、脂肪異栄養症治療の市場規模がもっとも大きいのはドイツで、約9,400万米ドルです。フランスがこれに続き、その他の欧州4ヶ国と英国の市場シェアは小さいです。
• REGN4461は現在Regeneron PharmaceuticalsによるフェーズII試験が行われており、脂肪異栄養症に対する有望な新治療法です。レプチン受容体作動薬として設計されたこの治験中の治療は、代謝バランスを回復させインスリン感受性を改善することにより、脂肪異栄養症の管理における大きなアンメットニーズに対応する可能性を秘めています。

当レポートでは、脂肪異栄養症の主要7市場（米国、ドイツ、スペイン、イタリア、フランス、英国、日本）について調査分析し、各地域の市場規模、現在の治療法、アンメットニーズ、新薬などの情報を提供しています。

目次

第1章 重要考察

第2章 レポートのイントロダクション

第3章 脂肪異栄養症市場の概要

• 脂肪異栄養症の市場シェアの分布（2023年）
• 脂肪異栄養症の市場シェアの分布（2034年）

第4章 調査手法

第5章 エグゼクティブサマリー

第6章 疾患の背景と概要

• イントロダクション
• 脂肪異栄養症の原因
• 脂肪異栄養症に関連する危険因子
• 兆候と症状
• 脂肪異栄養症の病態生理学
• 脂肪異栄養症の合併症
• 臨床症状

第7章 診断

• 脂肪異栄養症の診断アルゴリズム
• 鑑別診断

第8章 脂肪異栄養症の治療

• 治療アルゴリズム

第9章 脂肪異栄養症の診断と治療のガイドライン

第10章 結論

第11章 疫学と患者人口

• 主な調査結果
• 前提条件と根拠：主要7市場
• 主要7市場の脂肪異栄養症の総患者数
• 米国
• 欧州4ヶ国・英国
• 日本

第12章 ペイシェントジャーニー

第13章 承認された治療法

• MYALEPT（metreleptin）：Amryt Pharma
• EGRIFTA/EGRIFTA SV（tesamorelin）：Thera Technologies

第14章 新治療法

• REGN4461：Regeneron Pharmaceuticals

第15章 市場の分析

• 主な調査結果
• 主要7市場の脂肪異栄養症の総市場規模
• 米国市場
  • 米国の脂肪異栄養症の総市場規模
  • 米国の脂肪異栄養症の市場規模：治療法別
• 欧州4ヶ国・英国市場
  • 欧州4ヶ国・英国の脂肪異栄養症の総市場規模
  • 欧州4ヶ国・英国の脂肪異栄養症の市場規模：治療法別
• 日本市場
  • 日本の脂肪異栄養症の総市場規模
  • 日本の脂肪異栄養症の市場規模：治療法別

第16章 KOLの見解

第17章 市場の障壁

第18章 市場促進要因

第19章 SWOT分析

第20章 アンメットニーズ

第21章 付録

第22章 DelveInsightのサービス内容

第23章 免責事項

第24章 DelveInsightについて

List of Tables

• Table 1: Summary of Lipodystrophy Market, and Epidemiology (2020-2034)
• Table 2: Key Events
• Table 3: Prevalence of Lipodystrophy
• Table 4: Gender-specific Cases of Lipodystrophy
• Table 5: Cases of Lipodystrophy Based on Subtypes
• Table 6: Total Cases of Lipodystrophy in the 7MM (2020-2034)
• Table 7: Total Cases of Lipodystrophy in the United States (2020-2034)
• Table 8: Subtype-specific Cases of Lipodystrophy in the US (2020-2034)
• Table 9: Gender-specific Cases of Lipodystrophy in the United States (2020-2034)
• Table 10: Total Cases of Lipodystrophy in EU4 and the UK (2020-2034)
• Table 11: Subtype-specific Cases of Lipodystrophy in EU4 and the UK (2020-2034)
• Table 12: Gender-specific Cases of Lipodystrophy in EU4 and the UK (2020-2034)
• Table 13: Total Cases of Lipodystrophy in Japan (2020-2034)
• Table 14: Subtype-specific Cases of Lipodystrophy in Japan (2020-2034)
• Table 15: Gender-specific Cases of Lipodystrophy in Japan (2020-2034)
• Table 16: Comparison of Marketed Drugs
• Table 17: Patent Expiry Timeline
• Table 18: MYALEPT (metreleptin) Clinical Trial Description, 2022
• Table 19: EGRIFTA/EGRIFTA SV (tesamorelin) Clinical Trial Description, 2022
• Table 20: Comparison of Emerging Drugs
• Table 21: WAYLIVRA; Clinical Trial Description, 2022
• Table 22: Mibavademab; Clinical Trial Description, 2022
• Table 23: Empagliflozin; Clinical Trial Description, 2022
• Table 24: Key Market Forecast Assumptions for WAYLIVRA (volanesorsen)
• Table 25: Key Market Forecast Assumptions for Mibavademab (REGN 4461)
• Table 26: Key Market Forecast Assumptions for Empagliflozin
• Table 27: Market Size of Lipodystrophy in the 7MM in USD million (2020-2034)
• Table 28: Market Size of Lipodystrophy by Current and Emerging Therapies in the 7MM, in USD million (2020-2034)
• Table 29: Market Size of Lipodystrophy in the United States, USD million (2020-2034)
• Table 30: Market Size of Lipodystrophy by Current and Emerging Therapies in the US, in USD million (2020-2034)
• Table 31: Market Size of Lipodystrophy in EU4 and the UK, USD million (2020-2034)
• Table 32: Market Size of Lipodystrophy by Current and Emerging Therapies in EU4 and the UK, in USD million (2020-2034)
• Table 33: Market Size of Lipodystrophy in Japan , USD million (2020-2034)
• Table 34: Market Size of Lipodystrophy by Current and Emerging Therapies in Japan, in USD million (2020-2034)

List of Figures

• Figure 1: Lipodystrophy syndromes
• Figure 2: Lipodystrophy versus obesity
• Figure 3: Diagnostic Approach
• Figure 4: Total Cases of Lipodystrophy in the 7MM (2020-2034)
• Figure 5: Total Cases of Lipodystrophy in the United States (2020-2034)
• Figure 6: Subtype-specific Cases of Lipodystrophy in the United States (2020-2034)
• Figure 7: Gender-specific Cases of Lipodystrophy in the United States (2020-2034)
• Figure 8: Total Cases of Lipodystrophy in EU4 and the UK (2020-2034)
• Figure 9: Subtype-specific Cases of Lipodystrophy in EU4 and the UK (2020-2034)
• Figure 10: Gender-specific Cases of Lipodystrophy in EU4 and the UK (2020-2034)
• Figure 11: Total Cases of Lipodystrophy in Japan (2020-2034)
• Figure 12: Subtype-specific Cases of Lipodystrophy in Japan (2020-2034)
• Figure 13: Gender-specific Cases of Lipodystrophy in Japan (2020-2034)
• Figure 14: Patient Journey
• Figure 15: Market Size of Lipodystrophy in the 7MM in USD million (2020-2034)
• Figure 16: Market Size of Lipodystrophy by Current and Emerging Therapies in the 7MM, in USD million (2020-2034)
• Figure 17: Market Size of Lipodystrophy in the US, USD millions (2020-2034)
• Figure 18: Market Size of Lipodystrophy by Current and Emerging Therapies in the US, USD million (2020-2034)
• Figure 19: Market Size of Lipodystrophy in EU4 and the UK, USD million (2020-2034)
• Figure 20: EU4 and the UK Market Size of Lipodystrophy by Current and Emerging Therapies, in USD million (2020-2034)
• Figure 21: Market Size of Lipodystrophy in Japan, USD millions (2020-2034)
• Figure 22: Market Size of Lipodystrophy by Current and Emerging Therapies in Japan, USD million (2020-2034)
• Figure 23: Unmet Needs

Key Highlights:

• Lipodystrophy is a rare disorder characterized by the abnormal distribution of body fat. It can result in the loss of fat tissue (lipoatrophy) or the accumulation of fat in abnormal areas of the body (lipohypertrophy).
• According to DelveInsight's estimates for 2023, there were approximately 3,077 prevalent cases of rare disease lipodystrophy across the 7MM, with the United States accounting for 35% of these cases.
• In 2023, 93% of diagnosed lipodystrophy cases were partial lipodystrophy, predominantly affecting females. This is largely because familial partial lipodystrophy (FPL), a common type, is linked to genetic mutations in the LMNA or PPARG genes, which are more prevalent in women.
• In 2023, approximately 30% of lipodystrophy cases in the United States were classified as congenital generalized lipodystrophy. This condition involves near-total loss of body fat, resulting in prominent muscles, severe insulin resistance, early-onset diabetes, hypertriglyceridemia, and non-alcoholic fatty liver disease (NAFLD).
• The US FDA has approved two therapies for Lipodystrophy, including MYALEPT (metreleptin) and EGRIFTA/EGRIFTA SV (tesamorelin) by Amryt Pharma and Thera Technologies, respectively.
• The pipeline for Lipodystrophy remains relatively limited, with only a few companies advancing their candidates through different stages of clinical trials. Notable candidates include REGN4461 by Regeneron Pharmaceuticals, which is currently in Phase II. The rarity of Lipodystrophy presents challenges in patient recruitment for clinical trials, which in turn slows the progress of developing new treatment options.
• The US represents the largest share of the lipodystrophy market, driven by the high prevalence of the condition and the availability of approved therapies. MYALEPT (metreleptin) by Amryt Pharma is a key player, with its leptin-based treatment generating significant revenue.

DelveInsight's "Lipodystrophy - Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the indication Lipodystrophy, historical and forecasted epidemiology as well as the Lipodystrophy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Lipodystrophy market report provides real-world prescription pattern analysis, approved drugs, market share of individual therapies, and historical and forecasted 7MM Lipodystrophy market size from 2020 to 2034. The report also covers current Lipodystrophy treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Lipodystrophy Understanding and Treatment Algorithm

Lipodystrophy Overview, Country-Specific Treatment Guidelines and Diagnosis

Lipodystrophy is a rare condition marked by abnormal fat distribution, either as fat loss (lipoatrophy) or fat accumulation (lipohypertrophy). It can be congenital (inherited) or acquired later in life. The disorder often leads to significant metabolic complications. Congenital lipodystrophy includes types like congenital generalized lipodystrophy (CGL), which involves widespread fat loss and metabolic issues like insulin resistance, and familial partial lipodystrophy (FPL), where fat is lost in some areas and accumulates in others. Acquired lipodystrophy can develop later, sometimes related to autoimmune diseases. Acquired generalized lipodystrophy (AGL) causes widespread fat loss, while acquired partial lipodystrophy (APL) leads to progressive upper body fat loss with lower body accumulation. HIV-associated lipodystrophy can occur as a side effect of antiretroviral therapy.

Symptoms include fat loss in the face, arms, legs, and buttocks, abnormal fat accumulation in the neck and trunk, and metabolic issues like insulin resistance and diabetes.

Diagnosis involves clinical evaluation, metabolic assessment, imaging studies like MRI or CT scans, and, in some cases, genetic testing or fat biopsy.

Lipodystrophy Treatment

Treatment for lipodystrophy primarily focuses on managing the metabolic complications that result from abnormal fat distribution, such as insulin resistance, diabetes, and hypertriglyceridemia. The approach is personalized based on the type of lipodystrophy and the severity of symptoms. Metabolic management includes medications like metformin for insulin resistance and insulin therapy for diabetes, along with drugs such as fibrates or statins to lower triglyceride levels and reduce cardiovascular risk. Lifestyle modifications involving diet and exercise are also essential for controlling blood sugar levels and maintaining overall health.

Lipodystrophy Epidemiology

The Lipodystrophy epidemiology chapter in the report provides historical as well as forecasted prevalence in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The Lipodystrophy epidemiology is segmented with detailed insights into:

• Total cases of Lipodystrophy in the 7MM [2020-2034].
• Subtype-specific Cases of Lipodystrophy in the 7MM [2020-2034]
• Gender-specific Cases of Lipodystrophy in the 7MM [2020-2034]

Key Epidemiological Highlights

• According to DelveInsight's estimates for 2023, there were approximately 3,077 prevalent cases of rare disease lipodystrophy across the 7MM, with the United States accounting for 35% of these cases.
• In 2023, the EU4 countries and the UK together accounted for approximately 60% of the total lipodystrophy cases.
• In 2023, approximately 30% of lipodystrophy cases in the United States were classified as congenital generalized lipodystrophy. This condition involves near-total loss of body fat, resulting in prominent muscles, severe insulin resistance, early-onset diabetes, hypertriglyceridemia, and non-alcoholic fatty liver disease (NAFLD).
• In 2023, 93% of diagnosed lipodystrophy cases were partial lipodystrophy, predominantly affecting females. This is largely because familial partial lipodystrophy (FPL), a common type, is linked to genetic mutations in the LMNA or PPARG genes, which are more prevalent in women.

Lipodystrophy Drug Chapters

The drug chapter segment of the Lipodystrophy report encloses a detailed analysis of Lipodystrophy emerging and approved candidates. It also deep dives into the Lipodystrophy pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Approved Drugs

MYALEPT (metreleptin): Amryt Pharma

Metreleptin mimics the physiological effects of leptin by binding to and activating the human leptin receptor, which belongs to the Class I cytokine family of receptors that signals through the JAK/STAT transduction pathway. Only the metabolic effects of metreleptin have been studied. No effects on the distribution of subcutaneous fat are expected.

The US Food and Drug Administration (FDA) approved MYALEPT (metreleptin) in 2014, Myalepta is indicated as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy patients: with confirmed congenital generalized lipodystrophy or acquired generalized lipodystrophy in adults and children 2 years of age and above.

EGRIFTA/EGRIFTA SV (tesamorelin): Thera Technologies

EGRIFTA/EGRIFTA SV is a growth hormone-releasing factor (GRF) analog indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. EGRIFTA is used to reduce lipodystrophy caused by certain HIV medications. EGRIFTA is not a weight-loss medication and should not be used to treat obesity.

The US Food and Drug Administration (FDA) approved EGRIFTA in 2010.

Emerging Drugs

REGN4461: Regeneron Pharmaceuticals

Mibavademab (REGN 4461) is a leptin receptor (LEPR) agonist antibody developed by Regeneron pharmaceuticals to treat generalized lipodystrophy. The drug is currently in Phase II clinical trials conducted on patients with generalized lipodystrophy and familial partial lipodystrophy.

Subcutaneous Metreleptin: Amryt Pharma

A 12-month randomized, multicenter, double-blind, placebo-controlled Phase III (METRE-PL) study to evaluate the safety and efficacy of daily subcutaneous metreleptin treatment in subjects with partial lipodystrophy.

Lipodystrophy Market Outlook

The market for lipodystrophy treatments is evolving with a focus on both established and emerging therapies. In the United States, the market is dominated by key approved therapies like MYALEPT (metreleptin) and EGRIFTA/EGRIFTA SV (tesamorelin), with substantial revenue contributions from these treatments.

• The US represents the largest share of the lipodystrophy market, driven by the high prevalence of the condition and the availability of approved therapies. MYALEPT (metreleptin) by Amryt Pharma is a key player, with its leptin-based treatment generating significant revenue, approximately $880,000.
• Among the EU4 countries and the UK, Germany has the largest market size for lipodystrophy treatments, valued at approximately USD 94 million. France follows, while the other EU4 countries and the UK have smaller market shares.
• REGN4461, currently in Phase II trials by Regeneron Pharmaceuticals, represents a promising emerging therapy for lipodystrophy. This investigational treatment, designed as a leptin receptor agonist, has the potential to address significant unmet needs in managing lipodystrophy by restoring metabolic balance and improving insulin sensitivity.

Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2024-2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Lipodystrophy Activities

This section provides insights into different therapeutic candidates. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

This section covers information on collaborations, acquisitions and mergers, licensing, and patent details for emerging therapies.

KOL Views

To keep up with the real-world scenario in current market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Their opinion helps understand and validate current treatment patterns of Lipodystrophy. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy.

Market Access and Reimbursement

The section provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, descriptive overview of Lipodystrophy, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country specific treatment guidelines.
• Additionally, an all-inclusive account of the current therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Lipodystrophy market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Lipodystrophy.

Lipodystrophy Report Insights

• Patient Population
• Therapeutic Approaches
• Lipodystrophy Pipeline Analysis
• Lipodystrophy Market Size and Trends
• Existing and future Market Opportunity

Lipodystrophy Report Key Strengths

• Eleven Years Forecast
• 7MM Coverage
• Lipodystrophy Epidemiology Segmentation
• Inclusion of Country specific treatment guidelines
• KOL's feedback on approved therapies
• Key Cross Competition
• Conjoint analysis
• Drugs Uptake and Key Market Forecast Assumptions

Lipodystrophy Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

• What is the growth rate of the 7MM Lipodystrophy treatment market?
• What was the Lipodystrophy total market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
• Is there any unexplored patient setting that can open the window for growth in the future?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the current options for the treatment of Lipodystrophy?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Lipodystrophy Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Detailed analysis and ranking of class-wise potential current therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Lipodystrophy Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Lipodystrophy in 2023
• 3.2. Market Share (%) Distribution of Lipodystrophy in 2034

4. Methodology

5. Executive Summary

6. Disease Background and Overview

• 6.1. Introduction
• 6.2. Causes of Lipodystrophy
• 6.3. Risk factors associated with Lipodystrophy
• 6.4. Signs and Symptoms
• 6.5. Pathophysiology of Lipodystrophy
• 6.6. Complications of Lipodystrophy
• 6.7. Clinical Manifestations

7. Diagnosis

• 7.1. Diagnostic Algorithm of Lipodystrophy
• 7.2. Differential diagnosis

8. Treatment of Lipodystrophy

• 8.1. Treatment Algorithm

9. Diagnostic and Treatment Guidelines for Lipodystrophy

10. Conclusion

11. Epidemiology and Patient Population

• 11.1. Key Findings
• 11.2. Assumptions and Rationales: 7MM
• 11.3. Total Prevalent Cases of Lipodystrophy in the 7MM
• 11.4. United States
  • 11.4.1. Total cases of Lipodystrophy in the US
  • 11.4.2. Subtype-specific Cases of Lipodystrophy in the US
  • 11.4.3. Gender-specific Cases of Lipodystrophy in the US
• 11.5. EU4 and the UK
  • 11.4.1. Total cases of Lipodystrophy in the EU4 and the UK
  • 11.4.2. Subtype-specific Cases of Lipodystrophy in EU4 and the UK
  • 11.4.3. Gender-specific Cases of Lipodystrophy in EU4 and the UK
• 11.6. Japan
  • 11.4.1. Total cases of Lipodystrophy in Japan
  • 11.4.2. Subtype-specific Cases of Lipodystrophy in Japan
  • 11.4.3. Gender-specific Cases of Lipodystrophy in Japan

12. Patient Journey

13. Approved Therapies

• 13.1. MYALEPT (metreleptin): Amryt Pharma
  • 13.1.1. Product Description
  • 13.1.2. Regulatory Milestones
  • 13.1.3. Other Developmental Activities
  • 13.1.4. Clinical Development
• 13.1. EGRIFTA/EGRIFTA SV (tesamorelin): Thera Technologies
  • 13.1.1. Product Description
  • 13.1.2. Regulatory Milestones
  • 13.1.3. Other Developmental Activities
  • 13.1.4. Clinical Development

14. Emerging Therapies

• 14.1. REGN4461: Regeneron Pharmaceuticals
  • 14.1.1. Product Description
  • 14.1.2. Regulatory Milestones
  • 14.1.3. Other Developmental Activities
  • 14.1.4. Clinical Development

15. Market Analysis

• 15.1. Key Findings
• 15.2. Total Market Size of Lipodystrophy in the 7MM
• 15.3. US Market
  • 15.3.1. Total Market Size of Lipodystrophy in the US
  • 15.3.2. Market Size of Lipodystrophy by Therapies in the US
• 15.4. EU4 and the UK Market
  • 15.4.1. Total Market Size of Lipodystrophy in EU4 and the UK
  • 15.4.2. Market Size of Lipodystrophy by Therapies in EU4 and the UK
• 15.5. Japan Market
  • 15.5.1. Total Market Size of Lipodystrophy in Japan
  • 15.5.2. Market Size of Lipodystrophy by Therapies in Japan

16. KOL Views

17. Market Barriers

18. Market Drivers

19. SWOT Analysis

20. Unmet Needs

21. Appendix

• 21.1. Bibliography
• 21.2. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight